Effective treatment for Idiopathic Pulmonary Fibrosis (IPF) patients now available
Anti-fibrotic medications are drugs that inhibit or reduce fibrosis in the lung. Two such drugs, pirfenidone and nintedanib, which have been proved to slow the disease progression in IPF patients, have now been recommended for listing on the Pharmaceutical Benefits Scheme (PBS). One of these medications, nintedanib, has now been listed on the PBS and subsidised by the Australian Government (effective 1 May), thereby making it affordable for patients. The PBS decision to list and subsidise pirfenidone is still pending and we hope a decision to list this medication is forthcoming.
For further information on access to IPF medications, please talk to your respiratory physician.
Nationwide participants help Australian IPF Registry
Figure 1: Geographical distribution of participants in the Australian IPF Registry. The green circles represent
the location of Registry participants (Reproduced with permission from the European Respiratory Society ©. European Respiratory Journal Feb 2017, 49 (2) 1601592; DOI: 10.1183/13993003.01592-2016).
Participants from all over Australia generously contribute information about their health to the Australian IPF Registry and this was well illustrated by research published recently in the European Respiratory Journal (Figure 1). The research titled, Baseline Characteristics of Idiopathic Pulmonary Fibrosis: Analysis from the Australian IPF Registry, provides important information on IPF in Australia and in particular demonstrates that there is a wide diversity of co-morbidities and disease severity.
The Australian IPF Registry aims to maximise recruitment into IPF clinical trials, thereby supporting the development of novel therapies. Further information can be found at www.lungfoundation.com.au or phone 1800 654 301.